LTRN is a stranger to high volume. For the last 2 quarters, it hasn't traded more than 355k shares on a GOOD day. Many days even see less than 100k shares trade. The current OS on it is 11 M suggesting the float is, at the very most, 11 million as of the last reported OS. This morning the company announced FDA news and was granted Orphan Drug Designation for its LP-184 pancreatic cancer treatment. "This orphan designation is one of many upcoming milestones that we expect to achieve for our LP-184 program in pancreatic cancer. We recently reported that LP-184 demonstrated significant and rapid pancreatic tumor shrinkage, by over 90%, within in-vivo mouse models over 8 weeks. In comparison, the tumors in the untreated mice grew by over eleven-fold in volume during the same 8-week period. We are excited to advance this groundbreaking research to help patients suffering from this devastating disease where the benefits of current treatment options are very limited." - Panna Sharma, President & CEO of Lantern Pharma.Taking a look at the chart and fib retracement using recent lows and the anchor, you can see how the 786 fib line has remained a consistent pivot on the chart. It was a previous support that LTRN bounced off of. Now, over more recent weeks it has become more of a resistance with the stock now treading water during premarket trading on Aug 11. Though LTRN has broken above the 50DMA for the first time in quite a while, it was rejected during premarket trading when it tested the 200DMA level around $16. Considering all of these major areas of focus, it will be interesting to see if enough momentum is in play for any meaningful move to persist or if LTRN will fall back once again.
If there's one thing that has been in the spotlight this summer it has been cancer treatment stocks.
Sanofi (SNY) Acquired Translate Bio (TBIO)
Bristol Myers' (BMY) Opdivo Showed Significant Growth
Merck's drug gained FDA approval
CYTK broke out big sparking a biotech rally
Fate Therapeutics Progressed with its trial
You also had a bunch of momentum building off the back of biotech breakouts, in general this week. "a few former penny stocks on Robinhood raised eyebrows in the analyst community. In fact, these analysts have given targets between 23% and 368% higher than where these stocks currently trade."
Quote Source & Read more: Hot Stocks To Watch On Robinhood With Analyst Targets Up To 368%
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.